Data on the effectiveness and toxicity of high-dose melphalan in patients with renal impairment (RI) are lacking. We evaluated the impact of RI on outcomes of patients with multiple myeloma treated with melphalan 200 mg/m 2 (Mel200) and autologous stem cell transplantation. Similar baseline characteristics were seen among 46 patients with creatinine clearance (CrCl) o 60 mL/min (median 50 mL/min, range 20-59) and 103 patients with CrCl ⩾ 60 mL/min (median 83 mL/min, range 60-128). Patients with CrCl o60 mL/min had longer time to neutrophil (P = 0.008) and platelet engraftment (P o 0.001). Diarrhea, duration of total parenteral nutrition use and infection were significantly higher in the CrCl o 60 mL/min group. With a median follow-up of 35 months (range 2-132) in the CrCl o60 mL/min group and 47 months (range 1-45) in the CrCl ⩾ 60 mL/min group, overall survival was comparable between the two groups. Median treatment-free survival was longer in the RI group (37 vs 17 months, P = 0.0025). Multivariate analysis showed CrCl o 60 mL/min (hazard ratio (HR) 3.5), and prior proteasome inhibitor therapy (HR 2.441) both predicted longer treatment-free survival. We consider Mel200 safe and effective in patients with CrCl between 30 and 60 mL/min.
INTRODUCTION
Renal impairment (RI) is a common feature in patients with multiple myeloma (MM) and its presence at the time of diagnosis is a risk factor for shorter survival. 1 A series of large multicenter trials identified renal insufficiency in almost a third of MM patients who experienced death within 60 days of diagnosis. 2 Moreover, data from the United States Renal Data System revealed a significant difference in the 2-year all-cause mortality in patients with end-stage renal disease when it was due to MM compared with other causes. 3 Treatment options in patients with MM and RI have been limited. To avoid severe toxicities, many active drugs have been studied at reduced dosages.
High-dose melphalan with autologous stem cell transplant (ASCT) has been shown to significantly improve PFS in patients with MM and is considered a standard of care in the initial treatment of myeloma as well as for relapsed disease. [4] [5] [6] Standard pretransplant conditioning consists of 200 mg/m 2 of melphalan (Mel200) based on increased tolerability and efficacy compared with other regimens. 5, 6 Most studies evaluating Mel200 excluded patients with RI (42 mg/dL) owing to concerns of increased treatment-related morbidity and non-relapse mortality. There are widely conflicting clinical and pharmacokinetic data in this patient population. In fact, pharmacokinetic studies suggest that melphalan clearance is mostly independent of renal clearance. 7 Although the available literature provides insufficient information to draw evidence-based conclusions on how to optimally dose melphalan in the conditioning regimen, many physicians empirically follow dose reduction for patients who present with RI. 8, 9 Given this lack of data evaluating efficacy and toxicity of high-dose melphalan in RI, we compared the clinical outcomes and tolerability of Mel200 in patients with normal and impaired renal function.
PATIENTS AND METHODS
We conducted a retrospective study evaluating the efficacy and toxicity of high-dose melphalan in patients with MM receiving ASCT at the University of Illinois Hospital and Health Sciences System between January 2001 and September 2012. Approval of the University of Illinois at Chicago Institutional Review Board was obtained before study commencement. Hospital pharmacy records were searched for melphalan administration to identify patients who received Mel200.
Patients
Patients analyzed in this study were required to have a diagnosis of symptomatic MM as defined by standard criteria and were excluded if they were younger than 18 years of age, received melphalan 140 mg/m 2 , were receiving hemodialysis at the time of transplant or if they received a previous allogeneic stem cell transplant. In addition, patients who underwent a second autologous transplant within 6 months of the first were excluded. Patients who underwent a second autologous transplant outside of this time period were included for assessment of toxicity, although evaluation for survival and progression was only assessed from the time of first transplant. Measurements of creatinine clearance (CrCl) (calculated using Cockcroft-Gault equation) were taken on admission (day − 2 of ASCT) to avoid overestimation after hydration with IV fluids. Patients were assigned into the RI group if they had a CrCl o 60 mL/min based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI), which defines these patients as having chronic kidney disease.
Treatment
Patients were admitted to hospital on day − 2 and remained in hospital until complete recovery. All patients received melphalan 200 mg/m 2 IV in equally divided doses on 2 consecutive days followed by ASCT 24 h later. All grafts were peripheral blood mobilized stem cells with a minimum CD34+ cell dose of 2 × 10 6 per kilogram. Standard anti-microbial prophylaxis consisted of levofloxacin and fluconazole during periods of neutropenia and acyclovir until day +30. In addition, patients received Pneumocystis jiroveci prophylaxis with either sulfamethoxazoletrimethoprim or pentamidine for 6 months. Patients received G-CSF daily from day +5 or from time of neutropenia until neutrophil engraftment.
Outcome measurements
Response to treatment was defined by standard International Myeloma Working Group definitions. Treatment-free survival (TFS) was defined as time from first autologous transplant to initiation of the subsequent line of therapy. Overall survival (OS) was defined as time from first autologous transplant to death. Survival duration was censored at the last outpatient clinic follow-up if the patient was still alive. Mucositis and diarrhea were graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events grading system version 4. In addition, further measures of these toxicities such as duration of total parenteral nutrition use and diarrhea were assessed. Neutrophil and platelet engraftment were defined as the first of three consecutive days of granulocyte count above 0.5 × 10 9 /L and first of seven consecutive days with a platelet count above 20 × 10 9 /L and no requirement of platelet transfusion, respectively.
Statistical analysis
Categorical data were analyzed by χ 2 test. Continuous data were analyzed by t-test. OS and PFS were assessed using the Kaplan-Meier method. The Cox regression method was used for multivariate analysis of factors influencing TFS. The analysis was performed using GraphPad Prism (GraphPad, La Jolla, CA, USA) or SAS (SAS Institute, Cary, NC, USA).
RESULTS

Baseline characteristics
Of the 149 evaluable transplants included in the analysis, 46 patients had a CrCl o 60 mL/min and 103 patients had CrCl ⩾ 60 mL/min. Median creatinine clearance was 50 mL/min in the RI cohort and 83 mL/min (60-128) in the normal renal function cohort (P o0.001). Baseline characteristics are summarized in Table 1 . The median age was 61 years (38-77) in the CrCl o60 mL/min group and 58 years (34-74) in the CrCl ⩾ 60 mL/min group (P = 0.01). No other significant difference was observed among baseline demographic characteristics between the two groups. Most patients in the two groups were diagnosed with stage 3 disease using the International Staging System. Patients in both groups received a median of two therapies before ASCT. The majority of patients in both groups had received either an immunomodulator drug-or proteasome inhibitor-based regimens. Of note, 30% of patients in the o 60 mL/min group and 25% of patients in the ⩾ 60 mL/min group had received prior autologous transplant. The median time from diagnosis to first ASCT was similar in both groups (11.5 versus 11 months, P = NS).
Engraftment, toxicity and hospitalization The mean dose of CD34 + cells was 5.8 × 10 6 /kg in the CrCl 460 mL/min group and 5.4 x 10 5 /kg in the CrCl o 60 mL/min group (P = NS). Patients with a CrCl o 60 mL/min had longer time to neutrophil and platelet engraftment (Figure 1 ). Median time to neutrophil engraftment was 10 (range 7-12) and 9 (range 8-13) days in patients with CrCl o 60 mL/min and ⩾ 60 mL/min, respectively (P = 0.008). Median time to platelet engraftment was 12 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) ) and 10 (8-18) days in each group, respectively (P o 0.001). The median duration of hospitalization was significantly longer in patients with RI (14 (range 12-36) versus 16 (range 11-47) days, P = 0.02). There were no treatment-related deaths at 100 days post ASCT observed in either group. The following variables were analyzed as measures of toxicity: grade of diarrhea; grade of mucositis; duration of diarrhea; duration of TPN use; documented infections; occurrence of febrile neutropenia; and IV antibiotic use. Comparisons were done between patients with CrCl o60 and ⩾ 60 mL/min (Figure 2 ). An additional comparison between patients with CrCl o 50 and ⩾ 80 mL/min was performed to characterize any differences among extremes of renal function. Thirteen (28%) patients in the CrCl o 60 mL/min group experienced grade 4 mucositis compared with 16 (16%) patients in the CrCl ⩾ 60 mL/min group (P = 0.09). Significantly more patients in the CrCl o 60 mL/min group experienced grade 2-4 diarrhea (P = 0.04) and had documented infections (P = 0.02) as compared with the CrCl ⩾ 60 mL/min group. When patients with CrCl o 50 mL/min were compared with those with CrCl ⩾ 80 mL/min, significantly more patients were found to have grade 2-4 diarrhea (P = 0.009). Both duration of TPN use and duration of diarrhea were greater in the RI group compared with the normal renal function group (P = 0.02 and o 0.001, respectively). Finally, there was no negative impact of MEL200 on renal function in the RI group. 
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Disease response, TFS and OS The International Myeloma Working Group response criteria were used to define CR, very good partial response, partial response, stable disease and progressive disease for patients in whom the data were available. Response was assessed immediately before autologous transplant and again between 90 and 180 days after transplant. Pretransplant data were available in 73% of the patients in the CrCl ⩾ 60 mL/min group and 65% of patients in the CrCl o 60 mL/min group. Post-transplant data were available in 58% of the patients in the CrCl ⩾ 60 mL/min group and 57% of the patients in the CrCl o60 mL/min group. Although an increase in the CR rate after ASCT was seen in both groups (20% in RI vs 14% in normal renal function), this was found to be significant only in the CrCl o 60 group (P = 0.02). With a median follow-up of 35 months (2-132) in the CrCl o 60 mL/min group and 47 months (1-45) in the CrCl ⩾ 60 mL/min group (P = NS), we could not detect any significant difference in OS (Figure 3 ). However, median TFS was 37 months in the RI group and 17 months in normal renal function group (P = 0.0025). Given this difference in TFS, we analyzed whether more patients received post-ASCT maintenance therapy in the RI group. We instead found that significantly more patients in the normal renal function group were on maintenance treatment compared with the RI group (40% versus 9.8%, P = 0.0004). A multivariate Cox regression model to analyze the impact of several variables such as age, race, time to transplant, pretransplant response, FISH, karyotype, International Staging System stage, prior proteasome inhibitor or immunomodulator drug therapy, and number of prior therapies on TFS showed that CrCl o 60 mL/min (hazard ratio 3.5, P = 0.0004) and prior proteasome inhibitor therapy (hazard ratio 2.441, P = 0.025) both predicted longer TFS. Number of prior therapies (hazard ratio 0.7, P = 0.03) predicted for a shorter TFS. In this multivariate analysis, established prognostic factors such as FISH did not meet statistical significance owing to missing data.
DISCUSSION
The effectiveness and toxicity of high-dose melphalan in patients with RI has not been well studied, despite its routine application in clinical practice. We retrospectively evaluated MM patients at our institution who received Mel200 with either normal or impaired renal function defined as CrCl o60 mL/min. To our knowledge, this represents one of the largest comparisons of outcomes between patients with and without RI who all received Mel200. We show that although MM patients with RI receiving MEL200 before ASCT have an increased short-term toxicity, mortality is similar and TFS is prolonged compared with patients with normal renal function. The pharmacokinetic profile of melphalan has been previously described. Following IV administration, drug plasma concentrations decline rapidly with a terminal elimination half-life of 75 min. The drug is eliminated from the plasma primarily by chemical hydrolysis to monohydroxymelphalan and dihydroxymelphalan. These inactive metabolites appear in the urine within minutes of the drug administration. Spontaneous degradation accounts for most of the drug's elimination. 10 It is suggested that renal clearance contributes o 10-15% of the drug elimination. In the very limited pharmacokinetic studies that are available, patients with renal dysfunction appear to have similar pharmacokinetic profiles to those with normal creatinine clearance and no statistical correlations were seen between CrCl and area under the curve or plasma clearance of the drug. [10] [11] [12] Despite the limited pharmacokinetic data, previous published clinical experience clearly suggests increased toxicity in patients with RI. [13] [14] [15] [16] The Arkansas group has reported a prospective study evaluating the relationship between melphalan pharmacokinetics and renal function in 20 patients with MM. 17 Six patients had renal insufficiency (CrCl o 40 mL/min), including five on hemodialysis. All patients received Mel200. Although melphalan pharmacokinetics after the first dose were not adversely affected by impaired renal function, the authors observed that the plasma half-life and area under the curve curve differed by a factor of 10 and melphalan clearance by a factor of 5 between patients with the lowest and highest values, proving significant interindividual variation in melphalan elimination. In this small cohort, RI did not adversely affect neutrophil and platelet engraftment, transfusion requirements, incidence of severe mucositis or OS but was however associated with longer duration of fever and hospitalization. 17 Carlson et al. 18 conducted a retrospective single center study of 96 MM patients receiving Mel200 with ASCT. Chronic renal failure (GFR o 60 mL/min) was present in only 19 patients, with severe failure (GFR o 30 mL/min) in five patients, including one patient on hemodialysis. No relationship between GFR and stem cell collection yield, engraftment or the incidence of neutropenic fever was observed, although patients with RI were more often affected by severe mucositis. In addition, of the five patients with severe renal failure, two patients developed severe gastrointestinal bleeding and two patients developed pneumonia requiring ventilator support. The single patient who suffered transplant-related mortality was in the RI group. Lower iohexol clearance at the time of high-dose administration was found to have a poor impact on survival. Two other studies compare the Cr Cl <60
Cr Cl ≥60 Figure 1 . Cumulative time to neutrophil (left) and platelet engraftment (right). Median neutrophil engraftment was 10 days in the RI group and 9 days in the normal renal function group (P = 0.008). Median platelet engraftment was 12 days in the RI group and 10 days in the normal renal function group (P o0.001).
use of Mel200 with Mel140 in patients with RI and show that Mel140 was as effective as Mel200 and led to less nonhematologic toxicity. [19] [20] [21] Conversely, Parikh et al. 22 evaluated outcomes of 46 patients with MM and renal failure and showed that MEL200 was not associated with increased toxicity and renal function improved in 32% of patients. Despite these conflicting data, major working groups such as IMWG and ABSMT recommend reducing the dose from 200 to 100-140 mg/m 2 in patients with CrCl o 60 mL/min based on decreased tolerability in this population. 1, 23 Our results confirm these prior findings that patients with renal dysfunction experience short-term toxicity often observed after autologous transplant. This could be due to a portion of melphalan being renally cleared and potentially causing more toxicity. However, in our cohort we found that patients with RI had longer TFS, which we believe could be related to higher melphalan exposure. This was despite the fact that more patients in the normal renal function group received post-transplant maintenance therapy compared with the RI group. Additionally, in a multivariate analysis, our data illustrate that prior proteasome inhibitor treatment was one of the strongest predictors of prolonged TFS in the RI group. Based on these data, RI should not be a barrier to consideration for autologous transplant. We propose that patients with CrCl between 30 and 60 mL/min could receive Mel200. Future prospective studies comparing PK parameters and clinical outcomes between patients with normal renal function and those with RI would help validate our results. Cr Cl≥60 Figure 3 . Comparison of TFS and OS between the CrCl ⩾ 60 and o60 mL/min group. TFS was significantly prolonged (37 vs 17 months, P = 0.0025). There was no difference in OS.
